-
Carcinoma-in-situ AIS of early lung cancer
Time of Update: 2021-05-31
The treatment principle of AIS: Since cancer in situ grows slowly and will not metastasize, it is not dangerous to the body at this stage.
Image characteristics The treatment principle of AIS: Since cancer in situ grows slowly and will not metastasize, it is not dangerous to the body at this stage.
-
ASCO 2021: Summary Overview and Outlook 10 | Overview of Latest Breast Cancer Research (Triple Negative Breast Cancer Column)
Time of Update: 2021-05-31
org/record/201516/abstract" target="_blank" rel="noopener">A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131 For details, please refer to:asco.
-
Cancers: Biomarkers for immunotherapy of advanced gastroesophageal cancer
Time of Update: 2021-05-31
In addition to tumor type-independent markers MSI and TMB, the only validated predictive biomarker for immunotherapy in GEC is PD-L1 CPS.
gov/33916348/" target="_blank" rel="noopener">Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond .
-
Br J Cancer: Metformin can improve the prognosis of patients with gastric adenocarcinoma
Time of Update: 2021-05-31
The results of the study revealed that metformin can improve the survival rate of gastric adenocarcinoma patients with diabetes.
The results of the study revealed that metformin can improve the survival rate of gastric adenocarcinoma patients with diabetes.
-
Cell Death Differ: arginine methyltransferase PRMT5: a potential therapeutic target for basal-like breast cancer
Time of Update: 2021-05-31
The results of the study revealed that PRMT5 can methylate KLF5 to prevent its phosphorylation, ubiquitination and degradation, thereby promoting the maintenance and proliferation of breast cancer stem cells.
-
ASCO 2021: Summary Overview and Outlook 9 | First-line treatment options for colorectal cancer
Time of Update: 2021-05-31
Metastatic colorectal cancer health index scaleBetween March 2014 and March 2020, 254 patients were randomly assigned (127 capecitabine group and 127 AM group).
After 16 weeks of combination therapy , the capecitabine group without bevacizumab prolonged PFS.
-
JTO: Durvalumab in the treatment of NSCLE patients with stage III EGFR mutations after concurrent radiotherapy and chemotherapy
Time of Update: 2021-05-31
NSCLC patients with EGFR mutations do not benefit from duvalizumab and may be more prone to irAEs. Aredo, Jacqueline V.
Journal of Thoracic Oncology, Volume 16, Issue 6, 1030-1041 Durvalumab for Stage III EGFR -Mutated NSCLC After Definitive Chemoradiotherapy.
-
JCO: Can recurrent ovarian cancer benefit from carboplatin intraperitoneal hyperthermic perfusion chemotherapy during secondary cytoreductive surgery?
Time of Update: 2021-05-31
Ovarian cancerThis study aimed to evaluate the efficacy of carboplatin hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) in patients with recurrent ovarian cancer during secondary cytoreductive surgery .
This study aims to evaluate the efficacy of carboplatin intraperitoneal hyperthermic perfusion chemotherapy (HIPEC) in patients with recurrent ovarian cancer during secondary cytoreductive surgery.
-
Nat Commun: Comprehensive pharmacogenomics reveals subtype-specific treatment response for nasopharyngeal carcinoma
Time of Update: 2021-05-31
Nasopharyngeal carcinoma (NPC), as a malignant head and neck cancer, has a high incidence and usually occurs in certain regions, including Southeast Asia, North Africa, southern China, Hong Kong and Taiwan.
-
J Urol: Risk factors and prognosis of recurrence of urethral cancer after radical bladder cancer resection
Time of Update: 2021-05-31
82 years) are relatively longerIn general, carcinoma in situ, multifocal lesions and prostatic urethral involvement are pathological risk factors for recurrence of urethral cancer after radical cystectomy.
Carcinoma in situ, multifocal lesions and prostatic urethral involvement are the pathological risk factors for recurrence of urethral cancer after radical cystectomy.
-
Lancet Oncology: Avelumab combined with concurrent chemoradiotherapy and chemoradiotherapy alone in the treatment of locally advanced head and neck squamous cell carcinoma: a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial
Time of Update: 2021-05-31
The enrollment criteria of this study included patients aged 18 or over who had been histologically confirmed locally advanced oropharyngeal, hypopharyngeal, larynx, or oral squamous cell carcinoma that had not been treated before; ECOG score of 0 or 1 and Can receive radiotherapy and chemotherapy.
-
ASCO 2021: Summary Overview and Outlook 13|Special Research Express on Non-Small Cell Lung Cancer
Time of Update: 2021-05-31
immunitymethodThe researchers carried out a single-center, open-label, phase 1b trial, that is, combined with MCTL cells and teriprizumab (anti-PD-1 mAb) as a second-line treatment for advanced NSCLC.
org/record/196146/abstract">Single-arm Phase Ib study of multi-target cytotoxic T lymphocytes (MCTL) combined with teriprizumab as the second-line treatment of advanced non-small cell lung cancer (NSCLC)asco.
-
Ann Neurol: Mechanism of Ischemic Stroke in Cancer Patients
Time of Update: 2021-05-31
It can be seen that compared with the corresponding control group, cancer-related stroke patients have higher levels of coagulation, platelet and endothelial dysfunction markers, and more circulating microthrombi .
-
The "Newborn Reachable-Bethune·Cancer Patient Education" project was officially launched to escort cancer patients!
Time of Update: 2021-05-31
Fight the disease!Professor Wang Jialei, Department of Oncology, Cancer Hospital of Fudan University, said: " Lung cancer has always ranked first in the list of malignant tumors in China in recent years, including morbidity and mortality.
-
Nat Commun: mRNA therapy can treat hypoglycemia associated with glycogen storage disease and prevent liver cancer
Time of Update: 2021-05-31
preventionHypothetical model of hG6PC mRNA treatmentHypothetical model of hG6PC mRNA treatmentIn this study, the researchers encapsulated the engineered mRNA encoding human G6Pase-α in lipid nanoparticles (LNPs) to develop new mRNA therapies for GSD1a.
-
Br J Cancer: A randomized clinical trial study of TARGIT-IORT (targeted intraoperative radiotherapy during breast cancer lumpectomy)
Time of Update: 2021-05-31
The report showed that targeted intraoperative radiotherapy (TARGIT-IORT), which is risk-adapted during breast cancer lumpectomy, is as effective as total breast external beam radiotherapy (EBRT).
Targeted intraoperative radiotherapy (TARGIT-IORT), which is risk-adapted during breast cancer lumpectomy, is as effective as total breast external beam radiotherapy (EBRT).
-
Nat Commun: Identification of fecal microbial markers in the early detection of colorectal cancer
Time of Update: 2021-05-31
Changes in the composition of intestinal microbes in different disease statesChanges in the composition of intestinal microbes in different disease statesIn this study, the researchers conducted a comprehensive analysis of 1,056 public stool samples to identify microbial markers associated with adenomas for early detection of CRC.
-
Lancet Oncol: The efficacy of pembrolizumab as a single agent in the treatment of BCG-non-responsive high-risk non-muscle invasive bladder cancer
Time of Update: 2021-05-31
1016/S1470-2045(21)00147-9" target="_blank" rel="noopener">Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study .
1016/S1470-2045(21)00147-9" target="_blank" rel="noopener">Pembrolizumab monotherapy for the treatment of high- risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study in this message
-
JTO: Efficacy and safety of Sintilimab combined with gemcitabine+platinum in the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer: a randomized double-blind phase 3 clinical study (ORIENT-12).
Time of Update: 2021-05-31
ORIENT-12 is an evaluation conducted in 42 research centers in my country, Daboshu® (sintilimab injection) or placebo combined with gemcitabine and platinum (GP) for advanced or recurrent squamous non-small cells A randomized, double-blind, phase III controlled clinical trial on the effectiveness and safety of the first-line treatment of lung cancer (Clinicaltrials.
-
Chia Tai Tianqing approved the third high-end generic drug this year, pointing to Merck's heavy variety
Time of Update: 2021-05-23
Recently, Chia Tai Tianqing Pharmaceutical Group's application for the imitation of aprepitant capsules in category 4 was approved, making it the second domestic pharmaceutical company to be approved for the product and deemed to have been reviewed.
